Our Services
Medical Information
Helpful Resources
Published on: 10/22/2026
Bridging means your warfarin is paused before surgery and temporarily replaced with a shorter-acting injectable blood thinner, usually low molecular weight heparin, to cover the window when your INR drops too low to protect against clots. Most people stop warfarin about 5 days before a procedure, but only higher-risk patients (for example, those with a mechanical mitral valve, recent stroke, recent blood clot, or high-risk atrial fibrillation) are typically bridged, since bridging itself increases bleeding risk. Timing, dosing, the type of surgery, your kidney function, and when to restart both medications all change the plan, so the specifics vary from person to person. There are several important factors and exceptions to consider, including warning signs of clotting or bleeding after your procedure, which are explained in the complete answer below.
If you are noticing new leg swelling, chest pain, shortness of breath, unusual bruising, or bleeding while your anticoagulation is being adjusted, a free, instant symptom check can help you organize what you are feeling, understand which possibilities fit your situation, and decide how urgently to contact your surgeon or anticoagulation clinic.
Last reviewed for medical accuracy: 10/22/2026
If you take warfarin (Coumadin®) to prevent blood clots, managing it around the time of surgery requires a careful balance. “Bridging” is a strategy designed to minimize your risk of bleeding during an operation while still protecting you against clots. This guide explains:
Always speak to your doctor about any serious or life-threatening concerns.
Warfarin works by blocking vitamin K–dependent clotting factors. Its effect builds up over days and wears off slowly. That’s good for long-term care but tricky around surgery:
Bridging means temporarily switching from warfarin to a shorter-acting injectable anticoagulant—usually low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH):
Professional guidelines (American College of Chest Physicians, American Society of Hematology) recommend bridging for those at higher risk of clots.
Not every patient on warfarin requires bridging. Your physician will assess your individual risk of clotting versus bleeding. Common risk factors that favor bridging include:
High thromboembolic risk
Moderate risk (consider bridging based on patient factors)
Low thromboembolic risk (usually no bridging)
Your surgeon and prescribing doctor will weigh:
A typical warfarin-bridging schedule goes like this:
Stop warfarin about 5 days before surgery
Start LMWH when INR falls below target (often <2.0)
Hold the last LMWH dose ~24 hours before surgery
Perform surgery with standard precautions
Restart LMWH 12–24 hours after surgery
Continue LMWH until warfarin reaches therapeutic INR
Every plan may vary based on:
Benefits
Risks
Recent studies suggest that in some moderate-risk patients, skipping bridging may lead to less bleeding without increasing clot risk. Always follow your doctor’s personalized recommendation.
Pre-operative visit
Lab monitoring
Clear communication
Plan for emergencies
Stay in touch with your care team. Unexpected bleeding (e.g., large bruises, red or black stools, blood in urine) or signs of clot (leg swelling, sudden chest pain) need prompt evaluation.
Even with a solid bridging plan, watch for:
If you experience any of these, call your surgeon or primary doctor right away. For non-urgent concerns, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Your health situation is unique. This overview is for general information; it does not replace professional medical advice. Always:
If you have any life-threatening or serious concerns, seek immediate medical attention or call emergency services.
(References)
* Robinson GA, Nylander A. Warfarin and cataract extraction. Br J Ophthalmol. 1989 Sep;73(9):702-3. doi: 10.1136/bjo.73.9.702. PMID: 2804024; PMCID: PMC1041862.
* Spandorfer J, Merli G. Anticoagulation and elective surgery. N Engl J Med. 1997 Sep 25;337(13):938-9; author reply 939-40. doi: 10.1056/NEJM199709253371314. PMID: 9304058.
* Ansell JE. The perioperative management of warfarin therapy. Arch Intern Med. 2003 Apr 28;163(8):881-3. doi: 10.1001/archinte.163.8.881. PMID: 12719195.
* Douketis JD. Perioperative management of warfarin therapy: to bridge or not to bridge, that is the question. Mayo Clin Proc. 2008 Jun;83(6):628-9. doi: 10.4065/83.6.628. PMID: 18533078.
* Parvizi J, Huang R, Raphael IJ, Maltenfort MG, Arnold WV, Rothman RH. Timing of Symptomatic Pulmonary Embolism with Warfarin Following Arthroplasty. J Arthroplasty. 2015 Jun;30(6):1050-3. doi: 10.1016/j.arth.2015.01.004. Epub 2015 Jan 13. PMID: 25648058.
* Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad V, Ortel TL, BRIDGE Investigators. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 2015 Aug 27;373(9):823-33. doi: 10.1056/NEJMoa1501035. Epub 2015 Jun 22. PMID: 26095867; PMCID: PMC4931686.
* Weithman ME, Sieber A, Brewer J, Sheridan D. Educating patients about warfarin bridging. Nursing. 2019 Jul;49(7):18-19. doi: 10.1097/01.NURSE.0000558103.81656.b2. PMID: 31219980.
* Manista GC, Batko BD, Sexton AC, Edmiston TA, Courtney PM, Hannon CP, Levine BR. Anticoagulation in Revision Total Joint Arthroplasty: A Retrospective Review of 1917 Cases. Orthopedics. 2019 Nov 1;42(6):323-329. doi: 10.3928/01477447-20190906-02. Epub 2019 Sep 12. PMID: 31505013.
* Talari G, Demertzis ZD, Summey RD, Gill B, Kaatz S. Perioperative management of anticoagulation. Hosp Pract (1995). 2020 Dec;48(5):231-240. doi: 10.1080/21548331.2020.1792138. Epub 2020 Jul 13. PMID: 32627607.
* Kovacs MJ, Wells PS, Anderson DR, Lazo-Langner A, Kearon C, Bates SM, Blostein M, Kahn SR, Schulman S, Sabri E, Solymoss S, Ramsay T, Yeo E, Rodger MA, PERIOP2 Investigators. Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. BMJ. 2021 Jun 9;373:n1205. doi: 10.1136/bmj.n1205. Epub 2021 Jun 9. PMID: 34108229; PMCID: PMC8188228.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.